-
Andrew Garfield, Cate Blanchett And Oscar Isaac Among 58 Celebrities Who Urged Joe Biden To Call For 'Immediate Ceasefire In Gaza...Before Another Life Is Lost'
Saturday, October 21, 2023 - 3:55am | 767Read More...Fifty-eight prominent celebrities, including Andrew Garfield, Cate Blanchett, Hasan Minhaj, Joaquin Phoenix, Kristen Stewart, Jessica Chastain, Rooney Mara, and Oscar Isaac, have collectively penned an “open letter” to U.S. President Joe Biden amid the ongoing Israel-Hamas war. What...
-
From 'Twilight' To Comedy: Kristen Stewart, Dylan Meyer Team Up For Stoner Chick Flick
Monday, August 28, 2023 - 4:15pm | 594Read More...By Lucía Tedesco via El Planteo Renowned actress Kristen Stewart and her partner, screenwriter Dylan Meyer, are collaborating on an upcoming movie centered around "stoner chicks." While Meyer is writing the comedy, Stewart will take on the lead role. Although details about their...
-
Why One Johnson & Johnson Analyst Sees Oklahoma Opioid Ruling As Near-Term Sentiment Positive
Tuesday, August 27, 2019 - 1:03pm | 829Read More...The Cleveland County District Court in Oklahoma ordered Johnson & Johnson (NYSE: JNJ) and its Janssen unit to pay $572 million to settle a lawsuit relating to their opioid drugs. The Analysts Morgan Stanley analyst David Lewis maintained an Equal-weight rating on Johnson & Johnson with...
-
Barclays Upgrades Becton Dickinson, Says Market Overreacted To FDA's Drug-Coated Balloon Update
Monday, May 13, 2019 - 11:43am | 375Read More...Becton Dickinson and Co’s (NYSE: BDX) stock has lost more than 10 percent since March 15 in response to the FDA update on drug-coated balloons, or DCBs. The market seems to have overreacted to the news, and the upcoming FDA Advisory Committee meeting scheduled for June 19-20 may...
-
2017 Promises To Be An Interesting Year For Edwards Lifesciences
Thursday, February 2, 2017 - 3:46pm | 294Read More...Deutsche Bank reiterated its Hold rating on Edwards Lifesciences Corp (NYSE: EW), despite a fourth quarter beat, on overhangs related to competition and decelerating growth trends. Edwards Lifesciences earned $0.75 a share for the quarter on revenue of $767.7 million, topping consensus estimate...
-
Deutsche Takes A Look At Johnson & Johnson's Patent Woes
Thursday, August 18, 2016 - 2:53pm | 276Read More...Deutsche Bank maintained its Buy rating on Johnson & Johnson (NYSE: JNJ) despite a federal judge invalidated the company's patent for blockbuster rheumatoid arthritis drug, Remicade. The ruling is in favor of Celltrion and Pfizer Inc. (NYSE: PFE), which can now sell its Remicade...
-
Johnson & Johnson Sales Fall: What The Street Is Saying Now
Tuesday, October 13, 2015 - 12:25pm | 431Read More...Johnson & Johnson (NYSE: JNJ)’s Q3 revenue came up short of consensus estimates, but the company managed a beat on its EPS number. The company also announced an additional $10 billion in share buybacks. Wall Street firms and the market seem split on how to interpret the company’s...
-
Johnson & Johnson Seen As 'Safe Haven' By These Experts
Tuesday, September 29, 2015 - 8:48am | 352Read More...Johnson & Johnson (NYSE: JNJ) shares have declined 13.28 percent year-to-date, from the high of $106.29 achieved on January 8. Deutsche Bank’s Kristen Stewart has upgraded the company to Buy, maintaining a price target of $110. Following meetings with the management, Stewart...
-
Deutsche Bank Upgrades Abbott Laboratories
Wednesday, October 29, 2014 - 8:33am | 157Read More...On Wednesday, analysts at Deutsche Bank upgraded shares of Abbott Laboratories (NYSE: ABT) from Hold to Buy and raised the price target from $42 to $54. Kristen Stewart offered reasons for the upgrade. Following a meeting with Abbott’s management, Deutsche Bank analysts "walked...
-
Stifel: CareFusion Corporation Deal May Have Far-Flung Effects
Tuesday, October 7, 2014 - 3:54pm | 331Read More...Becton, Dickinson and Co.'s (NYSE: BDX) planned $12 billion acquisition of CareFusion Corporation (NYSE: CFN) may have far-flung effects on the medical technology sector, an analyst said Tuesday. Stifel's Richard Wise said the deal may force C.R. Bard Inc. to "bulk up" with a...
-
Deutsche Bank Reiterates On Medtronic And Covidien Amid Acquisition Proposal
Tuesday, July 8, 2014 - 12:17pm | 169Read More...In a note released Tuesday morning, Deutsche Bank analyst Kristen Stewart reiterated a Buy rating on both Medtronic (NYSE: MDT) and Covidien plc (NYSE: COV) and raised her price targets from $74.00 to $85.00 and from $93.00 to $114.00, respectively. The change in price target comes amid a...
-
UPDATE: Deutsche Bank Initiates Coverage on Tandem Diabetes Care on Fair Valuation
Monday, December 9, 2013 - 9:58am | 137Read More...In a report published Monday, Deutsche Bank analyst Kristen Stewart initiated coverage on Tandem Diabetes Care (NASDAQ: TNDM) with a Hold rating and $26.00 price target. In the report, Deutsche Bank noted, “We are initiating coverage of Tandem Diabetes (TNDM) with a Hold rating and a PT of $26. We...
-
UPDATE: Deutsche Bank Downgrades Johnson & Johnson on Valuation
Wednesday, July 17, 2013 - 8:27am | 160Read More...In a report published Wednesday, Deutsche Bank analyst Kristen Stewart downgraded Johnson & Johnson (NYSE: JNJ) from Buy to Hold, but raised the price target from $92.00 to $93.00. In the report, Deutsche Bank noted, “Our Buy rating was based on our view that the stock's valuation...
-
Have You Been 'Victimized, Bullied and Misrepresented' Online?
Friday, April 19, 2013 - 2:20pm | 549Read More...Between revenge websites, consumer reviews, complaint sites and the proliferation of personal blogs, there are an infinite number of ways for individuals to share their grievances. This may be great for angry complainers, but it can be very detrimental to those whose names are dragged through the...
-
Medtronic Price Target Set At $52 By Credit Suisse (MDT)
Wednesday, February 24, 2010 - 11:06am | 115Read More...Medical device maker Medtronic (NYSE: MDT) is reiterated with an Outperform rating and a $52 price target by Kristen Stewart, CFA, of Credit Suisse. Medtronic's (NYSE: MDT) shares are currently trading at $42.95 per share. Ms. Stewart explains, "Medtronic’s quarter was far from pristine, but we...
